JP2008514196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514196A5 JP2008514196A5 JP2007532995A JP2007532995A JP2008514196A5 JP 2008514196 A5 JP2008514196 A5 JP 2008514196A5 JP 2007532995 A JP2007532995 A JP 2007532995A JP 2007532995 A JP2007532995 A JP 2007532995A JP 2008514196 A5 JP2008514196 A5 JP 2008514196A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- crge
- crgr
- mixture
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 241000894006 Bacteria Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241000194017 Streptococcus Species 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0421465.6A GB0421465D0 (en) | 2004-09-27 | 2004-09-27 | Group A streptococcus protein |
| PCT/IB2005/003087 WO2006035311A2 (en) | 2004-09-27 | 2005-09-27 | GROUP A STREPTOCOCCUS CrgE PROTEIN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514196A JP2008514196A (ja) | 2008-05-08 |
| JP2008514196A5 true JP2008514196A5 (enExample) | 2008-10-02 |
Family
ID=33397333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532995A Pending JP2008514196A (ja) | 2004-09-27 | 2005-09-27 | Ａ群連鎖球菌ＣｒｇＥタンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080131465A1 (enExample) |
| EP (1) | EP1794186A2 (enExample) |
| JP (1) | JP2008514196A (enExample) |
| CA (1) | CA2581966A1 (enExample) |
| GB (1) | GB0421465D0 (enExample) |
| WO (1) | WO2006035311A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939087B2 (en) | 2000-10-27 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from Streptococcus groups A & B |
| US7709009B2 (en) | 2003-07-31 | 2010-05-04 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| US8287885B2 (en) | 2007-09-12 | 2012-10-16 | Novartis Ag | GAS57 mutant antigens and GAS57 antibodies |
| CN114340648A (zh) * | 2019-08-19 | 2022-04-12 | 贝勒大学 | 引导性抗微生物肽的益生菌递送 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
| US7939087B2 (en) * | 2000-10-27 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from Streptococcus groups A & B |
| US8933029B2 (en) * | 2001-08-24 | 2015-01-13 | Carrus Capital Corporation | Antimicrobial and anti-inflammatory peptides |
| JP2003321392A (ja) * | 2002-04-30 | 2003-11-11 | Univ Nihon | 粘膜免疫ワクチン用アジュバント |
| GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| JP4366497B2 (ja) * | 2002-08-30 | 2009-11-18 | 独立行政法人農業・食品産業技術総合研究機構 | 生体膜に特異的に作用する新規なペプチド |
-
2004
- 2004-09-27 GB GBGB0421465.6A patent/GB0421465D0/en not_active Ceased
-
2005
- 2005-09-27 EP EP05789325A patent/EP1794186A2/en not_active Withdrawn
- 2005-09-27 CA CA002581966A patent/CA2581966A1/en not_active Abandoned
- 2005-09-27 WO PCT/IB2005/003087 patent/WO2006035311A2/en not_active Ceased
- 2005-09-27 US US11/664,019 patent/US20080131465A1/en not_active Abandoned
- 2005-09-27 JP JP2007532995A patent/JP2008514196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2292644A3 (en) | Small Streptococcus pyogenes antigens and their use | |
| CN103906535B (zh) | 与葡萄球菌蛋白a的抗体相关的组合物和方法 | |
| Ord et al. | A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein | |
| JP2010516290A5 (enExample) | ||
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| FI4074331T3 (fi) | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi | |
| JP2005504513A5 (enExample) | ||
| JP2011523550A5 (enExample) | ||
| JP2009540852A5 (enExample) | ||
| JP2008536483A5 (enExample) | ||
| JP2008546390A5 (enExample) | ||
| JP6251730B2 (ja) | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 | |
| JP2012522010A5 (enExample) | ||
| JP2014502253A5 (enExample) | ||
| US7160990B2 (en) | Antibodies to a fibrinogen binding protein of staphylococcus epidermidis | |
| EP4106803A1 (en) | Propionibacterium acnes prophylactic and therapeutic immune treatment | |
| CN105378479A (zh) | 用于预测免疫疗法的临床效果的方法 | |
| JP2006510353A (ja) | ハプトグロビン受容体リガンド結合と相互作用する分子の使用 | |
| WO2008084072A3 (en) | Protective proteins of s. agalactiae, combinations thereof and methods of using the same | |
| Lin et al. | Helicobacter pylori heat-shock protein 60 induces production of the pro-inflammatory cytokine IL8 in monocytic cells | |
| CN104138598B (zh) | 预防猪鼻支原体感染细胞的方法及制剂 | |
| WO2007005627A3 (en) | Tuberculosis antigen detection assays and vaccines | |
| JP2008516985A5 (enExample) | ||
| JP2008522632A5 (enExample) | ||
| JP2004533848A5 (enExample) |